Nitin Jain
@nitinjainmd
Professor, Dept of Leukemia, MD Anderson Cancer Center | Director, CAR-T Leukemia Program | #CLL #ALL #TcellRx | via @aiims_newdelhi | Tweets: my own opinions
ID: 2756778469
http://faculty.mdanderson.org/Nitin_Jain/Default.asp?SNID=0 22-08-2014 22:34:34
2,2K Tweet
9,9K Followers
736 Following
Treatment-free remission in non-transplanted Ph+ #ALL pts is feasible in carefully selected pts. Those in CR1 (n=6) who maintained CMR for >48 mos did not relapse following TKI discontinuation. MD Anderson Cancer Center #Leukemia doi.org/10.1002/cncr.3… ACS Journal Cancer #leusm
Wonderful to host Dr Deepam Pushpam from AIIMS, New Delhi at MDACC #CAR-T #Immunotherapy cc Dr Sameer Bakshi Ranjit Kumar Sahoo
👉Appreciation lunch for #CLL research team MD Anderson Cancer Center Thank you for your ongoing commitment to patient care and research and innovation. 🙏🏽🙏🏽👏👏 #EndCancer #EndCLL Bill Wierda, MD, PhD Hagop Kantarjian,MD
👉👉 Amazing Keynote talk by Dr Marco Ruella Marco Ruella to mark the start of 2-day CAR T and Bispecific focus meeting Noopur Raje Dr Sattva Neelapu
On the sidelines of CAR T and bispecific meeting in Boston Krina Patel Gurbakhash Kaur Bloodbytes
👋Pan Pacific meeting in Maui: 1. Early registration closes on April 11!! 2. Abstract deadline March 17! Merit awards available for trainees and new faculty members! Matt Lunning D.O. Nitin Jain University of Nebraska Medical Center unmc.edu/cce/pan-pacifi…
👉👉 Faculty pic from the recent CAR T and Bispecific meeting in Boston MD Education Noopur Raje Sattva Neelapu Marco Ruella Krina Patel Gurbakhash Kaur Yi Lin Bloodbytes Irene Ghobrial Tycel Phillips Marlise R. Luskin MD, MSCE Matthew Davids, MD, MMSc Sham Mailankody Matt Frank and many others
In our editorial on the new #LRF CLL consensus guidelines, Bita Fakhri , Nitin Jain and I highlight their value but stress the need for resource-specific guidance to address global disparities. Fred Hutch Cancer Center ashpublications.org/bloodadvances/…
📢CAR T-cells for relapsed/refractory B-cell malignancies in India: phase 1/2 trial 📈Safety: no ICANS, low incidence of severe CRS, manageable haematological toxicities, 2 treatment-related deaths. 🔍Activity: 73% overall response rate.Rahul Purwar 👇 shorturl.at/x11Ip
Incredibly proud of this groundbreaking CAR-T therapy research from Hasmukh Jain Manju Sengar Rahul Purwar Gaurav Narula MD and others at Tata Memorial Hospital ACTREC-TMC IIT Bombay that demonstrates what the outcomes can be when meaningful collaborations happen thelancet.com/journals/lanha…
Join Nitin Jain, Krish Patel & Meghan Thompson for a live TownHall on #CLL at #ASCO25! 📍 Grand Ballroom B, Hyatt Regency Chicago 📆 Sat, May 31 | 🕖 6:30 PM CDT/ 8:00 PM EDT Register ➡️ bit.ly/CLL-25T | @CLLSociety #Oncology #MedEd
Looking forward to this expert-led #CLL TownHall at #ASCO25! Join Nitin Jain, Krish Patel & Meghan Thompson for an engaging live discussion on Sat, May 31 at the Hyatt Regency Chicago. Dinner & CME included—don’t miss it! 🍽️🎓 🔗 bit.ly/CLL-25T @CLLSociety #Oncology
🎥 Hear from Dr. Krish Patel as he shares what to expect at PeerView’s TownHall symposium on #CLL care during #ASCO25! Join him, Nitin Jain, Meghan Thompson & CLL Society Inc. for this interactive session on 5/31. 📍 Grand Ballroom B, Hyatt Chicago 🔗 bit.ly/CLL-25T
Looking forward to #ASCO25 ASCO #Chicago Naveen Pemmaraju, MD Anand Patel Krish Patel Vivek Subbiah, MD
Join PeerView Krish Patel Nitin Jain Meghan Thompson tonight for a #CLL #CME session where your questions take center stage PeerView.com/2025CLL #ASCO25
